The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis

• Published in: Endocrine 2018-12, Vol.62 (3), p.535-545
• Main Authors: Li, Xuejing, Qie, Suhui, Wang, Xianying, Zheng, Yingying, Liu, Yang, Liu, Guoqiang
• Format: Article
• Language: English
• Subjects: Blood Glucose; Clinical trials; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Endocrinology; Glucagon; Glucagon-like peptide 1; Glucagon-Like Peptide-1 Receptor - agonists; Glucagon-Like Peptides - therapeutic use; Glucose; Glycated Hemoglobin A; Hemoglobin; Humanities and Social Sciences; Humans; Hypoglycemic Agents - therapeutic use; Internal Medicine; Medicine; Medicine & Public Health; Meta-Analysis; multidisciplinary; Patients; Peptides; Safety; Science; Treatment Outcome
• ISSN: 1355-008X; 1559-0100
• DOI: 10.1007/s12020-018-1708-z

Objectives To investigate the safety and efficacy of once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide as monotherapy or add-on to other antihyperglycaemic agents (AHAs) in patients with type 2 diabetes mellitus (T2DM). Methods PubMed, Embase, Cochrane library and ClinicalTrials.gov were searched from the inception to January 18, 2018. Randomised controlled trials (RCTs) comparing semaglutide with placebo or other AHAs in T2DM patients were included in our meta-analysis. Risk ratio (RR) and mean difference (MD) with 95% confidence intervals (CI) were used to evaluate the outcomes. Results A total of 11 studies with 9519 patients were included in our meta-analysis. The results revealed that compared with placebo or other AHAs, semaglutide had further reduced the level of haemoglobin A1c (HbA1c) [MD 1.03%, 95% CI (0.85%, 1.22%), p